Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2004; 92(03): 662-665
DOI: 10.1055/s-0037-1613737
DOI: 10.1055/s-0037-1613737
Case Report
Deep vein thrombosis after intravenous immunoglobulins associated with methylprednisolone
Authors
Further Information
Publication History
Received
30 December 2003
Accepted after revision
07 June 2004
Publication Date:
15 December 2017 (online)
-
References
- 1 Anderson Jr. FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107: I9-16.
- 2 Kaufman J, Khatri BO, Riendl P. Are patients with multiple sclerosis protected from thrombophlebitis and pulmonary embolism?. Chest 1988; 94: 998-1001.
- 3 No author listed. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990; 264: 3189-93.
- 4 Brannagan 3rd TH, Nagle KJ, Lange DJ. et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47: 674-7.
- 5 Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21: 171-85.
- 6 Woodruff RK, Grigg AP, Firkin FC. et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986; 02: 217-8.
- 7 Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992; 42: 257-8.
- 8 Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997; 124: 416-8.
- 9 Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 2000; 14 (Pt 4): 662-3.
- 10 Evangelou N, Littlewood T, Anslow P. et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003; 56: 308-9.
- 11 Sherer Y, Levy Y, Langevitz P. et al. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 133-7.
- 12 Haplea S, Farrar J, Gibson G. et al. Thromboembolic events associated with intravenous immunoglobulin therapy. Neurology 1997; 48: A54
- 13 Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002; 22: 1638-41.
- 14 Alliot C, Rapin JP, Besson M. et al. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 2001; 94: 187-8.
- 15 Tristani-Firouzi P, Petersen MJ, Saffle JR. et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-52.
- 16 Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75: 83-5.
- 17 Katz KA, Hivnor CM, Geist DE. et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003; 139: 991-3.
- 18 Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50: 172-5.
- 19 Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.
- 20 Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003; 73: 97-100.
- 21 Wolberg AS, Kon RH, Monroe DM. et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65: 30-4.
- 22 Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J Clin Immunol 1998; 18: 52-60.
- 23 Huszar G, Jenei B, Szabo G. et al. Detection of pyrogens in intravenous IgG preparations. Biologicals 2002; 30: 77-83.
- 24 Reiter M, Bucek RA, Koca N. et al. Deep vein thrombosis and systemic inflammatory response: a pilot trial. Wien Klin Wochenschr 2003; 115: 111-4.
- 25 Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature 1962; 195: 1214-5.
- 26 Cosgriff S. Thromboembolic complications associated with ACTH and cortisone therapy. JAMA 1951; 147: 924-6.
- 27 Conn DL, Tompkins RB, Nichols WL. Glucocorticoids in the management of vasculitis – a double edged sword?. J Rheumatol 1988; 15: 1181-3.
- 28 Laug WE. Glucocorticoids inhibit plasminogen activator production by endothelial cells. Thromb Haemost 1983; 50: 888-92.
- 29 Abramowicz D, Pradier O, De Pauw L. et al. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 1994; 46: 1596-602.
- 30 van Giezen JJ, Jansen JW. Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost 1992; 68: 69-73.
- 31 Muhlfelder TW, Niemetz J, Kang S. GLucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity. Blood 1982; 60: 1169-72.
- 32 Stolz E, Klotzsch C, Schlachetzki F. et al. High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol 2003; 49: 247-8.
- 33 Lieberman E, Heuser E, Gilchrist GS. et al. Thrombosis, nephrosis, and corticosteroid therapy. J Pediatr 1968; 73: 320-8.
- 34 Matusiewicz R, Stempniak M, Lebiedowski K. et al. The most frequent complications during long-term corticotherapy. Wiad Lek 1989; 42: 273-7.